Lysergic acid amide-induced posterior reversible encephalopathy syndrome with status epilepticus
- PMID: 18446448
- DOI: 10.1007/s12028-008-9096-5
Lysergic acid amide-induced posterior reversible encephalopathy syndrome with status epilepticus
Abstract
Introduction: Posterior reversible encephalopathy syndrome (PRES) is known to occur in association with several substances. However, lysergic acid amide (LSA) is not among the previously reported causes of PRES.
Methods: We report on a patient with PRES presenting as convulsive status epilepticus associated with hypertensive encephalopathy after LSA ingestion. Magnetic resonance imaging was performed and catecholamine metabolites assayed.
Results: The patient achieved a full recovery after aggressive antihypertensive therapy and intravenous anticonvulsivant therapy. The clinical history, blood and urinary catecholamine levels, and response to treatment strongly suggest that PRES was induced by LSA.
Conclusion: LSA, a hallucinogenic agent chiefly used for recreational purposes, should be added to the list of causes of PRES.
Similar articles
-
[Psychoactive effects of 'legal high': About lysergic acid amide (LSA)].Therapie. 2017 Oct;72(5):605-608. doi: 10.1016/j.therap.2017.01.012. Epub 2017 Mar 30. Therapie. 2017. PMID: 28457570 French.
-
Status epilepticus secondary to hypertensive encephalopathy as the presenting manifestation of Guillain-Barré syndrome.Pediatr Emerg Care. 2007 Sep;23(9):659-61. doi: 10.1097/PEC.0b013e31814b2ddd. Pediatr Emerg Care. 2007. PMID: 17876260
-
MR imaging findings of medulla oblongata involvement in posterior reversible encephalopathy syndrome secondary to hypertension.AJNR Am J Neuroradiol. 2009 Apr;30(4):755-7. doi: 10.3174/ajnr.A1337. Epub 2008 Oct 14. AJNR Am J Neuroradiol. 2009. PMID: 18854436 Free PMC article.
-
Posterior reversible encephalopathy syndrome in childhood: report of four cases and review of the literature.Pediatr Emerg Care. 2012 Feb;28(2):153-7. doi: 10.1097/PEC.0b013e3182442fe8. Pediatr Emerg Care. 2012. PMID: 22307182 Review.
-
Posterior reversible encephalopathy syndrome in intensive care medicine.Intensive Care Med. 2007 Feb;33(2):230-6. doi: 10.1007/s00134-006-0459-0. Epub 2006 Nov 21. Intensive Care Med. 2007. PMID: 17119920 Review.
Cited by
-
[Headache and hypertension. Myth and evidence].Nervenarzt. 2010 Aug;81(8):963-72. doi: 10.1007/s00115-010-2996-6. Nervenarzt. 2010. PMID: 20419365 Review. German.
-
Determinants of recovery from severe posterior reversible encephalopathy syndrome.PLoS One. 2012;7(9):e44534. doi: 10.1371/journal.pone.0044534. Epub 2012 Sep 14. PLoS One. 2012. PMID: 23024751 Free PMC article.
-
Duloxetine-related posterior reversible encephalopathy syndrome: A case report.Medicine (Baltimore). 2016 Aug;95(33):e4556. doi: 10.1097/MD.0000000000004556. Medicine (Baltimore). 2016. PMID: 27537580 Free PMC article.
-
Psychedelics, epilepsy, and seizures: a review.Front Pharmacol. 2024 Jan 12;14:1326815. doi: 10.3389/fphar.2023.1326815. eCollection 2023. Front Pharmacol. 2024. PMID: 38283836 Free PMC article. Review.
-
Lysergic Acid Amide (LSA), an LSD Analog: Systematic Review of Pharmacological Effects, Adverse Outcomes, and Therapeutic Potentials.Pharmacy (Basel). 2025 Jul 21;13(4):98. doi: 10.3390/pharmacy13040098. Pharmacy (Basel). 2025. PMID: 40700269 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources